Purchase this article with an account.
Manfred Zierhut, Tarek Bayyoud, Bianka Sobolewska, Christoph M E Deuter; Life Expectancy of Patients with Intraocular Lymphoma after Peripheral Blood Stem Cell Transplantation. Invest. Ophthalmol. Vis. Sci. 2014;55(13):3102.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Primary intraocular lymphoma (PIOL) is the ocular disorder with the shortest 5-year survival time. It is mostly a diffuse large B-cell non-Hodgkin lymphoma. Up to 80% are associated with or will develop CNS-lymphoma. This is the reason for treating even isolated ocular disease systemically. Current treatment involves mainly intravenous high dose methotrexate (MTX) for PIOL. Peripheral blood stem cell transplantation (PBSCT) has been shown to be very effective for primary CNS lymphoma.
Retrospective observational study of 5 patients with intraocular lymphoma without (n=2) or with CNS involvement (n=3). All patients had standardized clinical and ophthalmological assessments. All patients received PBSCT in addition to high dose intravenous MTX. Three of these patients received additional chemotherapeutics and 1 patient radiation therapy.
Five patients (3 female and 2 male) with intraocular lymphoma were included in this study. The mean age at the initial presentation was 55.2 years (range: 40-74 years). The mean time of survival, starting with the initial symptoms, was 77.2 months (range: 25-136 months). All patients showed complete response of their intraocular and CNS-lymphoma. Today all patients are alive without any signs of relapses.
Treatment of intraocular lymphoma with PBSCT in addition to chemotherapeutics resulted in all patients in complete remission and long survival time.
This PDF is available to Subscribers Only